Source: John Theurer Cancer Center From: prnewswire.com John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced today that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma (GBM). The trial, sponsored by Boston Biomedical, is evaluating DSP-7888, an investigational cancer vaccine, in combination with bevacizumab for recurrent disease. Glioblastoma is the …
Servier, in Collaboration with Allogene Therapeutics, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy
Source: Allogene Therapeutics Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma ALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion Regimen Paris (France) and South San Francisco, Calif. – January 28, 2019 – Servier, an independent international pharmaceutical company and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical- stage biotechnology company pioneering the …
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer
Source: OncoQuest, Inc. From: prnewswire.com OncoQuest Inc., a privately held, cancer immunotherapy company, has retained the services of IQVIA, a company formed through the merger of IMS Health and Quintiles, to manage OncoQuest’s planned Phase 3 clinical study in frontline ovarian cancer with the company’s lead product candidate, oregovomab, an anti-CA-125 antibody. OncoQuest will collaborate with IQVIA, a leading global …
Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor
From: prnewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission (complete response) after treatment …
PrimeVax Immuno-Oncology Signs Exclusive Worldwide Dengue Virus License with US Army for Cancer Treatments
Source: PrimeVax Immuno-Oncology From: pipelinereview.com Novel Therapy Would Be First in Cancer Patients Using Dengue Virus PrimeVax Immuno-Oncology, Inc. announced today that the company has just signed an exclusive, worldwide license with the US Army Medical Materials Development Activity, Ft. Detrick, MD, USAMMDA, authorizing PrimeVax to use dengue virus-1 #45AZ5 strain for treatment of cancer. “This is an unprecedented move,” …
Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer
Source: Veru, Inc. From: globenewswire.com Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that it has initiated and enrolled the first patient in a clinical trial of its proprietary, next generation prostate cancer drug, VERU-111. The open-label Phase 1b/2 clinical trial for VERU-111, a novel oral drug, will be evaluated in men with metastatic refractory prostate …
Clinical Trial Saves Life of Stage 4 Kidney Cancer Patient
By: Bianca Castro From: nbcdfw.com When a well-known journalist in Dallas learned he had stage 4 kidney cancer, he was told he had three, possibly four, years to live. One year, later, the tumor threatening his life is gone and it’s thanks to a clinical trial at UT Southwestern. Robert Wilonsky will tell you there’s nothing special about him. He’ll …
Practice-changing clinical trial reduces long-term radiotherapy side effects in women with breast cancer
From: icr.ac.uk Targeting or reducing the dose of radiotherapy for women with breast cancer after surgery can substantially reduce the side effects they experience, a large-scale clinical trial has shown. The trial also found some women were more likely to experience side effects than others – for example, women were more likely to report side effects if they were younger, …
PrimeVax Immuno-Oncology Receives IND Permission From FDA
Source: PrimeVax Immuno-Oncology, Inc. From: prnewswire.com PrimeVax Immuno-Oncology, Inc. announced today that the company has successfully received their Investigational New Drug (IND) Application permission from the FDA to begin running their first human clinical trial. “Our goal is simple: treat melanoma patients who have exhausted their options,” states Tony Chen, PrimeVax’s CEO. “It has been a long road, but we …
Breast Cancer Drug Promising in Phase 3 Trial
By: Steven Reinberg From: consumer.healthday.com For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests. The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing …